Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…
View Resource
New Biomarkers and Therapeutics Show Potential in Still's Disease
Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…
View Resource
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved…
View Resource
Sleep Apnea Smart Watches (10.13.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past…
View Resource
FDA Approves Canakinumab for Gout Flares
The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in…
View Resource
Mono- and Oligo- are Different (8.18.2023)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…
View Resource
EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…
View Resource
ICYMI: LAVLI – A New Autoinflammatory Disorder
Editor’s note: This article originally appeared March 28, 2023, and is being shared again…
View Resource
EULAR 2023 Notes from Milan (6.09.2023)
Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…
View Resource
AOSD: Young vs. Elderly Onset
Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…
View Resource